Genocea Biosciences Inc (GNCAQ)

[jondoeuk]

I have studied the posted, but the ORR for single-agent Keytruda ranges from 14-23%. The mPFS is around two months, mOS around eight months (up to 15 in some), and mDOR around 8-20 months (in a third trial it wasn't reacted at 2-30+ months).

So on the face of it TIL seems to have (some) activity. If IOVA produced a select (neoantigen-reactive) product, changed the ex vivo expansion, and knocked-out PD-1, I think the ORR would be above 50%. Also, there should be improvements in mPFS, mOS as well as mDOR.